drugset
drugset / Trial / NCT03985410

Study Evaluating the Effect of ETX2514 on Cardiac Repolarization in Healthy Male or Female Volunteers

NCT03985410 ↗

Phase 1 Completed 32 enrolled Entasis Therapeutics
RandomizedCrossoverTriple-blindTreatment

Summary

This study is being conducted to evaluate the effects of supratherapeutic ETX2514 plasma concentrations on the heart rate-corrected QT interval (QTc).

Timeline

Start
2019-05-23
Primary completion
2019-07-24
Completion
2019-07-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Durlobactam Small molecule 4 g Intravenous
Background Moxifloxacin Small molecule 400 mg Oral

Indications

Acinetobacter infectious disease